The U.S. Food and Drug Administration on Wednesday approved Infilbray (venglustat) tablets as the first approved therapy targeting neurological symptoms in Type 3 Gaucher disease in adults and pediatric patients who weigh at least 15 kilograms, according to the agency.

The FDA said Infilbray crosses the blood-brain barrier and reduces the buildup of harmful substances in the body and brain. Acting FDA Commissioner Kyle Diamantas, J.D., said the drug can “get to the source of the buildup driving the neurological symptoms.”

Type 3 Gaucher disease is a rare inherited disorder that prevents the body from breaking down fatty molecules known as glucosphingolipids because of a deficient or malfunctioning enzyme, the agency said. The disease affects organs, tissues, and the brain, causing problems with balance, coordination, speech, memory, and thinking. The FDA said Infilbray is a glucosylceramide synthase inhibitor that reduces harmful substance accumulation throughout the body and within the brain.

Approval was based on a randomized, double-blind, multicenter study of 43 patients aged 12 years and older with Type 3 Gaucher disease who had previously received enzyme replacement therapy and had achieved systemic disease stabilization, the agency said. Patients took daily oral Infilbray, while the comparison group got intravenous enzyme replacement every two weeks over a 52-week period. Effectiveness was assessed using two measures that captured neurological symptoms central to daily life, including ataxia and cognitive function. At Week 52, those treated with Infilbray showed improvement on a combined measure of these assessments compared to those receiving enzyme replacement therapy for non-neurologic manifestations, according to the FDA.

The most common side effects include gastrointestinal symptoms and adverse effects on mood, the agency said. The FDA also cited serious psychiatric risks, including suicidal ideation and behavior. Animal studies identified possible vision clouding in younger patients and developmental harm to a fetus if the drug is taken during pregnancy. The FDA said more information on side effects is available in the drug labeling.

The FDA granted Infilbray Orphan Drug designation and Priority Review. The approval was granted to Genzyme Corporation, a Sanofi Company, the agency said.